



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugaisky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Jeffrey T. Helvey  
Heldi L. Kraus  
Albert L. Ferro\*  
Donald R. Banowitz  
Peter A. Jackman  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Eldora Ellison Floyd  
Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaton  
Theodore A. Wood  
Elizabeth J. Haanes

Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Lhulier  
Rae Lynn P. Guest  
George S. Bardmesser  
Daniel A. Klein\*  
Jason D. Eisenberg  
Michael D. Specht  
Andrea J. Kamage  
Tracy L. Muller\*  
LuAnne M. DeSantis  
Ann E. Summerfield  
Aric W. Ledford\*  
Helene C. Carlson  
Timothy A. Doyle\*  
Gaby L. Longsworth  
Lori A. Gordon\*  
Nicole D. Dretar\*

Ted J. Ebersole  
Jyoti C. Iyer\*  
Laura A. Vogel  
  
**Registered Patent Agents\***  
Karen R. Markowicz  
Nancy J. Leith  
Matthew J. Dowd  
Aaron L. Schwartz  
Katrina Yujian Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Teresa A. Colella  
Jeffrey S. Lundgren  
Victoria S. Rutherford  
Michelle K. Holoubek  
Robert H. DeSels  
Simon J. Elliott

Julie A. Heider  
Mita Mukherjee  
Scott M. Woodhouse  
Michael G. Penn  
Christopher J. Walsh

**Of Counsel**  
Kenneth C. Bass III  
Evan R. Smith  
Marvin C. Guthrie

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

October 12, 2004

**WRITER'S DIRECT NUMBER:**  
(202) 772-8625  
**INTERNET ADDRESS:**  
ESTEFFE@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Mail Stop: Issue Fee**

Re: Allowed U.S. Patent Application  
Application No. 09/807,512 ; § 371 Date: April 8, 2002  
For: **Camel, An Alternative Translation Product of the  
Tumor Antigen Lage-1**  
Inventor: SCHRIER *et al.*  
Our Ref: 0652.2200000/EKS/M-M

Sir:

Transmitted herewith for appropriate action are the following documents:


1. Summary of the Substance of an Interview; and
2. One (1) return postcard

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.


The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Eric K. Steffe  
Attorney for Applicants  
Registration No. 36,688

EKS/M-M/ayd  
Enclosures



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHRIER *et. al.*

Application No.: 09/807,512

§ 371 Date: April 8, 2002

For: **Camel, An Alternative Translation  
Product of the Tumor Antigen Lage-1**

Confirmation No.: 9121

Art Unit: 1642

Examiner: Davis, Minh Tam B

Atty. Docket: 0652.2200000/EKS/M-M

**Summary of the Substance of an Interview**

*Attn: Mail Stop Issue Fee*

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants note that an Interview Summary (Paper No. 20040830) has been issued in the present matter. Hence, in accordance with 37 C.F.R. § 1.133(b) and MPEP § 713.04, Applicants' undersigned representative provides the following statement of the substance of the interview held with the Examiner in the above-indicated application.

Applicants' undersigned representative contacted the Examiner by telephone on August 30, 2004. During the interview, agreement was reached with respect to the claims: (1) Claims 15 and 22 were deemed allowable; (2) New claims directed to an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO:12 could be submitted and would be deemed allowable.

Applicants submitted new claims 40-42, directed to an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO:12, in an Amendment filed by facsimile on August 31, 2004. A Notice of Allowability, mailed

September 10, 2004, indicates that claims 15, 22 and 40-42 (renumbered as claims 1-5) have been allowed.

Applicants respectfully request that this statement be entered into the record. It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Stoffe  
Attorney for Applicants  
Registration No. 36,688

Date: 10/12/07

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600